# Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

> **NCT03632759** · EARLY_PHASE1 · COMPLETED · sponsor: **Carla Greenbaum, MD** · enrollment: 16 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT03632759
- **Lead sponsor:** Carla Greenbaum, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2021-11-09
- **Final completion:** 2021-11-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03632759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03632759, "Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03632759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*